Sanofi SA (NAS:SNY)
$ 48.29 -0.1 (-0.21%) Market Cap: 121.07 Bil Enterprise Value: 139.04 Bil PE Ratio: 26.55 PB Ratio: 1.57 GF Score: 84/100

Sanofi SA to Discuss the Collaboration with Sanofi to Deliver Inflammatory Bowel Disease Treatment Call Transcript

Oct 04, 2023 / 12:00PM GMT
Release Date Price: $53.83 (+0.47%)
Operator

Hello, and welcome to the Teva announces collaboration with Sanofi for anti-TL1A Therapy Conference Call. My name is Alex. I'll be coordinating on the call today. (Operator Instructions).

Now I hand it over to your host, Ran Meir, Head of Investor Relations. Please go ahead.

Ran Meir
Teva Pharmaceutical Industries Limited - Head of IR

Thank you, Alex. Welcome, everyone, to Teva's investor call where we'll discuss our recent collaboration with Sanofi focusing on Teva's anti-TL1A Assets TEV '574. Please take a moment to review our forward-looking statements on Slide 2. You can find more details on these statements in our PR and Form 8-K released this morning as well as in our SEC Form 10-K and 10-Q.

Today's agenda, feature Richard Francis, Teva's CEO, who will present an overview and the strategic significance of our collaboration. It will be followed by Dr. Eric Hughes, Teva's Head of R&D and Chief Medical Officer; who will be diving into the clinical program. Afterwards, Eli Kalif, our CFO, will elaborate on the transaction details and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot